Needham Maintains Buy on ResMed, Raises Price Target to $236
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson maintains a Buy rating on ResMed (NYSE:RMD) and raises the price target from $224 to $236.
April 26, 2024 | 10:24 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Mike Matson maintains a Buy rating on ResMed and raises the price target from $224 to $236.
The increase in price target by a reputable analyst suggests a positive outlook on ResMed's future performance, likely leading to increased investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100